RESEARCH · RESEARCH · #2847
Claude Sonnet 5 agent autonomously selected and delivered gene therapy in a mouse
Researchers at Exin Therapeutics used Anthropic’s Claude Sonnet 5 to analyze a mouse epilepsy model, choose a gene therapy, pick a brain target and stereotactic coordinates, and control a motorized surgical rig to inject the treatment; a licensed veterinarian approved each irreversible step and the mouse reportedly recovered. Mid-procedure the agent refused to continue after detecting a calibration error, and more capable Claude models (Opus 5/5.5) had earlier declined to perform the live procedure; the work is described in an X thread and a technical report is expected but not yet peer-reviewed.
KEY POINTS
- Researchers at Exin Therapeutics used Anthropic’s Claude Sonnet 5 to analyze a mouse epilepsy model, choose a gene therapy, pick a brain target and stereotactic coordinates, and control a motorized surgical rig to inject the treatment; a licensed veterinarian approved each irreversible step and the mouse reportedly recovered.
- Mid-procedure the agent refused to continue after detecting a calibration error, and more capable Claude models (Opus 5/5.5) had earlier declined to perform the live procedure; the work is described in an X thread and a technical report is expected but not yet peer-reviewed.
- This demonstrates LLM-based agents directly controlling lab hardware and choosing treatments for living animals, highlighting new alignment, safety, and biosecurity challenges.
WHY IT MATTERS
This demonstrates LLM-based agents directly controlling lab hardware and choosing treatments for living animals, highlighting new alignment, safety, and biosecurity challenges.